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Abstract
Background: Lymphomatous meningitis (LM) represents a severe complication of malignant
lymphomas. While clinical suspicion is raised by symptoms ranging from mild disturbances of
sensation to severe pain or impaired consciousness, the definite diagnosis of LM is often difficult to
obtain. Since B-cell lymphomas are clonally restricted to express either kappa or lambda
immunoglobulin light chain, we hypothesised that analysis of free light chain (FLC) ratios might
facilitate the diagnosis of LM.
Methods:  Kappa and lambda FLC were measured using a novel nephelometric assay in
cerebrospinal fluid (CSF) and serum from 17 patients. 5/17 suffered from LM as demonstrated by
cytology, immunocytology, and/or imaging procedures.
Results: Measurement of FLC concentrations in CSF was achieved for all 17 patients. FLC levels
in CSF were lower than serum FLC levels in samples for the same patient obtained at the same
time (p < 0.01). CSF and serum FLC concentrations correlated weakly in all patients irrespective
of LM status. Significantly more patients with cytopathologically and immunohistochemically proven
LM displayed abnormal kappa/lambda FLC ratios in CSF compared to individuals with no LM (p <
0.01).
Conclusion: This is the first report demonstrating that a significant proportion of LM patients
display an abnormal kappa/lambda FLC ratio in the CSF.
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Background
Systemic intermediate- and high-grade Non-Hodgkin's
Lymphomas (NHL) carry a substantial risk of central nerv-
ous system (CNS) complications, and are sometimes
accompanied by lymphomatous meningitis (LM) [1-4].
Cytopathologic assessment of cerebrospinal fluid (CSF)
represents the standard diagnostic procedure. Current
imaging technologies have low sensitivity and specificity
with respect to LM [5]. To increase the sensitivity of
screening protocols for LM, multiple CSF punctures or
immunocytology may be performed. However, normal
CSF counts and/or normal CSF cell morphology do not
rule out LM [3].
Assessment of free immunoglobulin light chains in CSF
may improve the diagnostic investigation of LM. While
most immunoglobulin light chains are bound to immu-
noglobulin heavy chains to form complete antibody mol-
ecules, excess light chains are produced and secreted as
free light chains (FLC). Kappa and lambda FLC can be
measured quantitatively in serum and urine using a novel
nephelometric immunoassay. In normal individuals,
serum concentrations of kappa FLC and lambda FLC
range from 3.3 to 19.4 mg/l and 5.7 to 26.3 mg/l, respec-
tively. Serum FLC ratios (kappa/lambda) lying outside the
normal range (0.26 to 1.65, [6]) indicate monoclonal FLC
production arising as a result of clonal expansion [6,7].
Serum FLC levels and ratios are now routinely measured
to diagnose and monitor disease progression and
response to therapy in light chain multiple myeloma [8],
nonsecretory myeloma [9], intact immunoglobulin mye-
loma [10,11] primary AL amyloidosis [12], and to risk
stratify patients with monoclonal gammopathy of
unknown significance (MGUS) [13]. B-cell Non-Hodg-
kin's Lymphomas likewise exhibit a light chain restriction,
so that measuring free light chain concentrations in CSF
could particularly aid the diagnosis of LM.
Methods
Patients
Between December 2005 and August 2006, we obtained
CSF and peripheral blood samples from 17 consecutive
patients with clinically suspicion of LM who underwent
diagnostic lumbar punctures. All lumbar punctures were
clinically indicated and patients gave their informed con-
sent prior to CSF and peripheral blood sampling. For
patient's characteristics refer to table 1.
Routine CSF assessment
All CSF samples were routinely assessed for cell count,
protein, glucose, and lactate content. Furthermore, micro-
biological and virological investigations were performed
as per routine protocol for suspected bacterial or viral
meningitis [14,15]. All CSF samples were also evaluated
cytopathologically. For this purpose, 200 μl undiluted
CSF was centrifuged using a Shandon Cytospin 3 centri-
fuge at 500 rpm for 5 minutes onto a glass slide. Samples
were then stained according to the Pappenheim method.
If dubious, additional cytospins were stained immunohis-
tochemically according to the alkaline phosphatase-anti-
alkaline phosphatase (APAAP) method with antibodies
against the pan-B-cell antigen CD20, the kappa light
chain, the lambda light chain, or the pan-T-cell marker
CD3.
Routine imaging
The majority of patients with suspected LM received a
computed tomography and/or a magnetic resonance
imaging of the brain as part of the diagnostic work-up
prior to lumbar puncture.
Free light chain assay
FLC analysis was performed using the serum free light
chain assay (Freelite™ – The Binding Site Ltd., Birming-
ham, UK) on peripheral blood and CSF samples obtained
at the same time. Freelite™ nephelometric assays [7] use
latex-bound anti-FLC antibodies, reacted with serum/CSF
samples on an automated BN Prospec nephelometer
(Dade-Behring, Schwalbach, Germany). According to the
manufacturer, the lower detection limit is 0.06 mg/l for
kappa FLC and 0.08 mg/l for lambda FLC. We used 0.10
mg/l as the lower limit for both assays. In our institution,
the inter-assay coefficients of variation (CV, n = 10) were
5.1% at 14.3 mg/l for kappa FLC and 3.6% at 28.1 mg/l
for lambda FLC assay in control sera provided by the man-
ufacturer. With these control sera, appropriately diluted
for the quality control of CSF measurements [16], inter-
assay CVs of 9.8% at 0.8 mg/l kappa FLC and 5.8% at 1.5
mg/l lambda FLC were determined.
Statistical analyses
Descriptive and comparative statistics were performed by
using the SPSS 12 software package. Mann-Whitney-tests
were applied for comparisons between groups. Correla-
tions were assessed by using Kendall-Tau-b correlation
coefficients. A two-sided p-value less than 0.05 was con-
sidered to indicate significance for all tests. Sensitivity and
specificity were calculated by using 2 × 2 tables on the
basis of the upper reference values of the respective light
chain serum values.
Results
Patients characteristics
Between 12/2005 and 08/2006 peripheral blood and CSF
samples from 17 patients with lymphomas were assessed.
14/17 experienced clinical symptoms highly suspicious of
LM and/or displayed suspect findings on imaging. In the
remaining 3 patients, lumbar puncture was indicated
according to recent diagnostic guidelines. Those com-
prised one ocular high-grade B-cell Non-Hodgkin's Lym-BMC Cancer 2007, 7:185 http://www.biomedcentral.com/1471-2407/7/185
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phoma (B-NHL), one B-NHL with a paravertebral
manifestation progressing into the spinal canal, and one
high-grade follicular lymphoma of the tonsil (Table 1).
By means of cytopathology and immunohistochemistry,
LM was diagnosed in 5 patients. The other 12 patients
demonstrated no definite evidence indicating LM follow-
ing routine assessment.
Patient characteristics, results from conventional CSF
diagnostics with/without immunohistochemistry, and
findings from CNS imaging are presented in table 1.
Comparison of free light-chain concentrations in CSF and 
serum
Kappa and lambda FLC were quantified in serum and CSF
for each patient (Table 2). Both kappa FLC and lambda
Table 2: Free light chain concentrations in CSF and serum *
Patient LM CSF-κ CSF-λ CSF-Ratio Serum-κ Serum-λ Serum-Ratio
1 Yes 30.1 1.4 21.3 41.9 1.6 26.2
2 Yes 6.4 0.4 15.0 13.3 1.2 11.5
3 Yes 3.0 0.8 3.8 14.4 17.4 0.8
4 Yes 5.3 0.1 53.0 868.0 0.7 1240.0
5 Yes 32.6 0.4 85.8 114.0 13.5 8.4
6 No 0.2 0.1 1.9 15.2 17.3 0.9
7 No 0.4 0.4 1.0 5.6 12.4 0.5
8 No 0.5 0.4 1.2 28.1 1.7 16.7
9 No 16.9 4.8 3.6 41.2 32.3 1.3
10 No 18.5 16.4 1.1 18.5 16.4 1.1
11 No 0.4 0.4 0.9 26.9 35.9 0.7
12 No 11.5 2.8 4.0 30.1 19.7 1.5
13 No 0.7 0.4 1.6 5.6 1.6 3.5
14 No 0.3 0.4 0.7 N.D. N.D. N.D.
15 No 0.3 0.7 0.4 8.9 11.4 0.8
16 No 10.2 2.7 3.7 39.3 33.1 1.2
17 No 0.5 0.4 1.2 18.6 15.6 1.2
* values for kappa and lambda given in mg/l.
LM – lymphomatous meningitis; CSF – cerebrospinal fluid; N.D. – not done
Table 1: Patients' characteristics
Patient Gender Age LM Diagnosis CT/MRI CSF cell count CSF cytology CSF-IC Light chain on 
primary
1 W 46 Yes CLL LM 1054 Lymphocytes Kappa Kappa
2 W 47 Yes LPL Focal lesions 25 Lymphocytes Kappa Kappa
3 M 64 Yes DLCL, Stage IV N.D. 109 Lymphoblasts N.D. N.D.
4 M 65 Yes LPL LM 113 Lymphocytes N.D. Kappa
5 M 68 Yes DLCL, Stage IVE NEM 24 Lymphocytes Kappa Kappa
6 M 28 No PTLPD, Stage IVE NEM <10 N.S.C. N.D. N.D.
7 M 29 No FL Stage Ie (tonsil) NEM <10 N.S.C. N.D. N.D.
8 M 37 No DLCL Stage II NEM <10 N.S.C. N.D. N.D.
9 M 46 No DLCL, Stage IVE NEM 23 N.S.C. N.D. Kappa
10 W 50 No DLCL, Stage III Focal Lesion <10 N.S.C. N.D. N.D.
11 M 63 No M. Hodgkin, Stage IV N.D. <10 N.S.C. N.D. No
12 W 66 No Intracerebral PTLPD Focal Lesion 119 Lymphocytes CD 3 N.D.
13 W 66 No Lymphoblastic T-NHL N.D. <10 N.S.C. N.D. No
14 M 73 No Ocular Lymphoma NEM <10 N.S.C. N.D. N.D.
15 M 77 No CLL, Parkinson's Disease NEM <10 N.S.C. N.D. No
16 M 79 No M. Hodgkin, Stage III NEM 27 N.S.C. N.D. No
17 M 82 No DLCL St. IE (Spinal Cord) N.D. 90 Lymphocytes CD3 N.D.
LM – lymphomatous meningitis; CT – computed tomography; MRI – magnetic resonance imaging; CSF – cerebrospinal fluid; IC – 
immuncytochemistry, CLL – chronic lymphocytic leukaemia; DLCL – diffuse large cell lymphoma; LPL – lymphoplasmocytic lymphoma, PTLPD – 
post-transplantation lymphoproliferative disorder; FL – follicular lymphoma; T-NHL – Non-Hodgkin's Lymphoma of T-cell origin.
NEM – no evidence of lymphomatous meningitis; N.S.C. – no suspicious cells; N.D. – not done; EP-4 – epithelial cell surface markerBMC Cancer 2007, 7:185 http://www.biomedcentral.com/1471-2407/7/185
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FLC levels were significantly higher in serum than in CSF
(p < 0.01) in patients with and without LM. In addition,
the range of kappa FLC levels was wider in serum than in
CSF. The range of CSF FLC ratios was found to be nar-
rower than the range of serum FLC ratios, but overall there
was no significant difference between the ratios in CSF
and serum (p = 0.53). Correlation coefficients between
CSF and serum samples revealed weak to moderate corre-
lations for kappa and lambda FLC (+0.47; +0.26) as well
as for the kappa/lambda FLC ratio (+0.51) (Table 3).
Comparison of FLC concentrations between patients with 
and without LM
We analysed CSF FLC concentrations in patients with and
without proven LM. Two patients with LM presented
kappa FLC levels in CSF greater than the upper limit of the
normal serum reference range. By contrast, patients with-
out LM displayed kappa FLC levels in CSF lower than the
upper limit of the normal serum reference range. Further,
the mean kappa FLC levels in CSF were approximately
threefold higher in patients with LM compared to those
without LM (15.5 mg/l vs, 5.0 mg/l; p = 0.06).  Also see
figure 1.
It is of note that no elevations of lambda FLC levels in CSF
were detected within the entire study population.
8/12 individuals without LM exhibited CSF kappa/
lambda FLC ratios within the serum reference range (0.26
to 1.65). In contrast, all (5/5) of the patients with proven
LM demonstrated CSF kappa/lambda FLC ratios outside
the serum reference range. The CSF kappa/lambda FLC
ratios in patients with and without LM was significantly
different (p < 0.01). Assessment of the sensitivity and spe-
cificity of CSF kappa/lambda FLC ratio for the diagnosis
of LM resulted in a sensitivity of 100% and a specificity of
67% (Table 4).
Clinical details of the individuals without proven LM but
with CSF kappa/lambda FLC ratios outside the serum ref-
erence range (4/12) were as follows: Patient 12 (CSF
kappa/lambda ratio of 4 (Table 2) had an intracerebral
manifestation of a post-transplantation lymphoprolifera-
tive disorder. While the CSF-FLC ratio suggested possible
LM, this was not supported by conventional diagnostics.
The patient died a few weeks after the initial lumbar punc-
ture due to disease progression. Patient 9 (CSF kappa/
lambda FLC ratio of 3.6) had clinical symptoms highly
suggestive of central nervous system (CNS) involvement
and lesions reminiscent of a stroke after CNS imaging.
Clinical symptoms quickly improved after empirical
intrathecal therapy with methotrexate combined with sys-
temic chemoimmunotherapy. Remarkably, the CSF
kappa/lambda FLC ratio decreased from 3.6 to 1.6, while
the serum kappa/lambda FLC ratio remained largely
unchanged at a value of 1.63 (data not shown), and sub-
sequent imaging of the brain displayed a recurrence of the
former lesions. Patient 6 (CSF kappa/lambda FLC ratio of
1.9) suffered from a post-transplantation lymphoma
without cerebral manifestation. Finally patient 16 (CSF
kappa/lambda FLC ratio of 3.7) had an Epstein Barr virus-
associated B-cell lineage Hodgkin's disease.
Discussion
Lymphomatous meningitis is a typical, but uncommon
manifestation of systemic lymphoma or primary CNS
lymphoma. To date, the diagnosis is generally obtained
through cytopathologic assessment of CSF. However, nor-
mal CSF cell counts do not rule out the presence of LM
and even repeated CSF examinations, immunohistochem-
istry, or flow cytometry do not generally enhance diagnos-
tic specificity [17-19].
Comparison of kappa FLC, lambda FLC, and kappa/lambda  FLC ratios in patients with and without lymphomatous men- ingitis Figure 1
Comparison of kappa FLC, lambda FLC, and kappa/lambda 
FLC ratios in patients with and without lymphomatous men-
ingitis.
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Table 3: Comparison of light chain concentrations in cerebrospinal fluid and serum in 17 patients
κ CSF κ Serum λ CSF λ Serum κ/λ CSF κ/λ Serum
Reference (mg/l) not defned 3.30–19.40 not defined 5.71–26.3 not defined 0.26–1.65
Range (mg/l) 0.2 – 32.6 5.6 – 868.0 0.1 – 16.4 0.7 – 35.9 0.4 – 85.8 0.5 – 1240.0
Mean ± SD 8.1 ± 10.1 80.6 ± 211.6 1.9 ± 3.9 14.5 ± 11.7 12.1 ± 23.9 82.3 ± 308.8
Correlation + 0.47 + 0.26 + 0.51
P for Difference < 0.01 < 0.01 0.53BMC Cancer 2007, 7:185 http://www.biomedcentral.com/1471-2407/7/185
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To evaluate the benefit of measuring FLC concentrations,
and the kappa/lambda FLC ratio, in the CSF for the diag-
nosis of LM, we performed a pilot study measuring FLC in
serum and CSF from 17 patients with lymphomas.
The data presented here demonstrates that quantification
of absolute FLC concentrations in CSF is possible in lym-
phoma patients. Interestingly, CSF FLC levels were signif-
icantly lower compared to serum FLC levels. This
observation might be explained due to the fact that nor-
mal CSF is largely devoid of FLC-producing B-cells, and
that only small amounts of immunoglobulin cross the
blood-brain barrier [20]. Supporting this suggestion,
patient 8 who displayed an abnormal serum kappa/
lambda FLC ratio of 16.7, but a normal CSF FLC ratio, had
a relapsed diffuse large cell lymphoma, a leachate of lym-
phoma cells into peripheral blood, and a large abdominal
lymphoma burden. This patient therefore had a poten-
tially disrupted blood-brain barrier.
A recent publication reported CSF FLC kappa levels in the
range 0.06 to 0.47 mg/l in patients with no oligoclonal
immunoglobulin banding after electrophoresis, undergo-
ing a routine CSF assessment [16]. For the patients in our
study without definite LM, and with a normal FLC kappa/
lambda ratio (8/12), the range was 0.3 to 18.5 mg/l. How-
ever, if the patient with a concentration of 18.5 mg/l is
excluded, the range for the remaining 7/8 patients was
between 0.3 and 0.7 mg/l. Thus, it is very likely that the
normal range of FLC concentrations in CSF is generally
below that reported in serum. These normal reference
ranges need to be confirmed by larger studies.
Of particular interest, we found that when comparing CSF
FLC ratios in patients with and without conventionally
proven LM, we detected significantly more patients with
abnormal CSF FLC kappa/lambda ratios (p < 0.01) in the
confirmed LM group. Indeed, all patients (5/5) with
proven LM exhibited abnormal CSF kappa/lambda FLC
ratios, while most (8/12) patients without definite LM
demonstrated normal CSF kappa/lambda ratios. It is of
note, however, that 2/4 patients (patient 9 and 12) with
abnormal CSF FLC ratios but without LM had definite or
very likely intracerebral lymphoma manifestations. LM is
far more likely to occur in these patients than in those
with systemic NHL without parenchymal involvement of
the brain.
Finally, it is of note that in our pilot study all patients with
definite LM exhibited a kappa light chain restriction.
Twice as many B cells in normal peripheral blood produce
kappa FLC as produce lambda FLC. It is likely that this
ratio will be reflected in there being twice as many B cell
NHL producing kappa FLC as lambda FLC. This produc-
tion ratio and the small number of patients included in
this pilot study might explain why we only detected LM in
NHL patients with a kappa light chain restriction. The util-
ity of the CSF kappa/lambda FLC ratio for the detection of
LM in NHL patients with a lambda light chain restriction
will be the subject of a future study involving a larger
number of patients.
Conclusion
In conclusion, we demonstrate for the first time that the
CSF kappa/lambda FLC ratio appears to be a promising
parameter for use in diagnosing lymphomatous meningi-
tis. Further research, including the confirmation of these
findings in a larger cohort of patients, might establish CSF
kappa and lambda FLC analysis as a novel diagnostic tool
for patients with suspected lymphomatous meningitis.
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